Renal Cell Carcinoma

BIONIKK Trial Sees Improved Responses with Molecularly-Guided Therapy in Patients with mRCC
September 23, 2020

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

Cabozantinib Plus Atezolizumab Shows Promising Clinical Activity in Advanced Clear Cell Renal Cell Carcinoma
September 21, 2020

“The combination of cabozantinib and atezolizumab demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” said investigator Sumanta Kumar Pal, MD.

Ipi-Nivo Combination Yields Improved Responses After 4-Year Follow-Up in Advanced RCC
September 19, 2020

The combination use of nivolumab plus ipilimumab, compared with sunitinib, continued to show benefit during a 4-year follow-up in patients with advanced renal cell carcinoma.